SCHEMBL4606034

SCHEMBL4606034

CCC(=O)Nc1ccc(Oc2ccccc2OC(F)(F)F)cc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2BP2 Q9Y6M1 1/20 0.51
KDM4E B2RXH2 6/20 0.47
ALDH1A1 P00352 5/20 0.47
PKM P14618 1/20 0.47
KCNK2 O95069 1/20 0.44
KCNK10 P57789 1/20 0.44
HSD17B10 Q99714 2/20 0.44
HIF1A Q16665 1/20 0.43
GAA P10253 1/20 0.43
F2R P25116 1/20 0.42
CDK2 P24941 1/20 0.42
RORC P51449 1/20 0.41
PYGM P11217 2/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
PYGL P06737 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603669 0.88 ALDH1A1 (0.53) KDM4EALDH1A1PKMHSD17B10GAA
SCHEMBL4619861 0.87 KDM4E (0.47) IGF2BP2KDM4EALDH1A1PKMHSD17B10
SCHEMBL4604701 0.86 IGF2BP2 (0.48) IGF2BP2KDM4EALDH1A1PKMKCNK2
SCHEMBL4604249 0.86 POLB (0.54) KDM4EALDH1A1PKMHSD17B10GAA
SCHEMBL4604536 0.83 RXRA (0.57) IGF2BP2KDM4EALDH1A1PKMHSD17B10
SCHEMBL4606033 0.83 RORC (0.47) IGF2BP2KDM4EALDH1A1PKMHSD17B10
SCHEMBL4604342 0.82 KDM4E (0.49) KDM4EALDH1A1PKMHSD17B10GAA
SCHEMBL4605135 0.82 KDM4E (0.49) KDM4EALDH1A1PKMHSD17B10GAA
SCHEMBL4604961 0.81 ALDH1A1 (0.48) KDM4EALDH1A1PKMHSD17B10GAA
SCHEMBL4603683 0.80 PYGM (0.62) IGF2BP2PYGMPYGLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 IGF2BP2 3325/4885KDM4E 2898/4885ALDH1A1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.